



## MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent  
Licensee of the Blue Cross and Blue Shield Association

# Medical Policy Total Ankle Replacement

## Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

## Policy Number: 193

BCBSA Reference Number: 7.01.77

## Related Policies

Subtalar Arthroereisis, #[299](#)

## Policy

### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Total ankle replacement, using a device which the FDA has approved, may be considered **MEDICALLY NECESSARY** in skeletally mature patients with moderate to severe ankle (tibiotalar) pain that limits daily activity, who have one of the following conditions:

- Arthritis in adjacent joints (i.e., subtalar or midfoot) OR
- Severe arthritis of the contralateral ankle OR
- Arthrodesis of the contralateral ankle, OR
- Inflammatory (e.g., rheumatoid) arthritis.

**Unless** absolute contraindication to ankle arthroplasty exist.

Absolute contraindications to ankle arthroplasty include ANY of the following:

- Extensive avascular necrosis of the talar dome OR
- Compromised bone stock or soft tissue (including skin and muscle)OR
- Severe malalignment (e.g., > 15 degrees) not correctable by surgery OR
- Active ankle joint infection OR
- Peripheral vascular disease, OR
- Charcot neuroarthropathy.

Total ankle replacement for all other indications is **INVESTIGATIONAL**.

## Prior Authorization Information

### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

## Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is <b>not required</b> .
Commercial PPO and Indemnity	Prior authorization is <b>not required</b> .
Medicare HMO Blue <sup>SM</sup>	Prior authorization is <b>not required</b> .
Medicare PPO Blue <sup>SM</sup>	Prior authorization is <b>not required</b> .

## CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

The above **medical necessity criteria MUST** be met for the following codes to be covered for **Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

### CPT Codes

CPT codes:	Code Description
27702	Arthroplasty, ankle; with implant (total ankle)
27703	Arthroplasty, ankle; revision, total ankle

### ICD-10 Procedure Codes

ICD-10-PCS procedure codes:	Code Description
0SRF0J9	Replacement of Right Ankle Joint with Synthetic Substitute, Cemented, Open Approach
0SRF0JA	Replacement of Right Ankle Joint with Synthetic Substitute, Uncemented, Open Approach
0SRF0JZ	Replacement of Right Ankle Joint with Synthetic Substitute, Open Approach
0SRG0J9	Replacement of Left Ankle Joint with Synthetic Substitute, Cemented, Open Approach
0SRG0JA	Replacement of Left Ankle Joint with Synthetic Substitute, Uncemented, Open Approach
0SRG0JZ	Replacement of Left Ankle Joint with Synthetic Substitute, Open Approach

## Description

Total ankle replacement is intended to improve function and reduce stress on adjacent joints. It has been performed in patients with severe rheumatoid arthritis, severe osteoarthritis, or post-traumatic osteoarthrosis. Total ankle replacement models can be broadly subdivided into two design types, fixed bearing and mobile bearing.

Fixed-bearing devices lock the polyethylene component into the baseplate, which provides greater stability, but increases constraint and edge-loading stress at the bone implant interface, potentially increasing risk of early loosening and failure.

Mobile-bearing systems have a polyethelene component that is unattached and articulates independently with both the tibial and talar components. These systems are less stable than fixed-bearing designs and have the potential for dislocation and increased wear of the polyethylene component.

Examples of fixed- bearing devices for total ankle replacement include the Agility Ankle Revision Prosthesis from DuPuy Orthopaedics, the Inbone™ Total Ankle from INBONE Technologies and the Eclipse from Kinetikos Medical. All fixed- bearing devices for total ankle replacement are considered investigational regardless of the commercial name, the manufacturer or FDA approval status except as noted in the policy statement.

Examples of mobile- bearing devices for total ankle replacement include the Scandinavian Total Ankle Replacement from Small Bone Innovations and the TNK ankle from Kyocera Corporation. All mobile-bearing devices for total ankle replacement are considered investigational regardless of the commercial name, the manufacturer or FDA approval status except as noted in the policy statement.

## Summary

For specific conditions, including presence of bilateral, subtalar or midfoot arthritis, ankle fusion is not indicated. Although total ankle systems are continuing to evolve, and long-term evidence is limited, short-term results suggest similar improvements in pain and function in comparison with arthrodesis, and mid-term results indicate 75-80% survival at 10-15 years. Therefore, in the absence of an established alternative for specific conditions, total ankle replacement may be considered medically necessary when those specified conditions are met.

## Policy History

Date	Action
2/2018	Clarified coding information.
11/2015	Added coding language.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes. Effective 10/2015.
2/2014	Coding information clarified.
12/2013	New references from BCBSA National medical policy.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
6/2011	Reviewed - Medical Policy Group – Orthopedics, Rehabilitation Medicine and Rheumatology. No changes to policy statements.
1/2011	BCBS Association National Policy Review No changes in policy statement.
7/2010	Reviewed - Medical Policy Group – Orthopedics, Rehabilitation Medicine and Rheumatology. No changes to policy statements.
6/01/10	Medical Policy #193 created.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. Guyer AJ, Richardson G. Current concepts review: total ankle arthroplasty. Foot Ankle Int 2008; 29(2):256-64.

2. Coetzee JC, Deorio JK. Total ankle replacement systems available in the United States. Instr Course Lect 2010; 59:367-74.
3. Haddad SL, Coetzee JC, Estok R et al. Intermediate and long-term outcomes of total ankle arthroplasty and ankle arthrodesis. A systematic review of the literature. J Bone Joint Surg Am 2007; 89(9):1899-905.
4. SooHoo NF, Zingmond DS, Ko CY. Comparison of reoperation rates following ankle arthrodesis and total ankle arthroplasty. J Bone Joint Surg Am 2007; 89(10):2143-9.
5. Krause FG, Windolf M, Bora B et al. Impact of complications in total ankle replacement and ankle arthrodesis analyzed with a validated outcome measurement. J Bone Joint Surg Am 2011; 93(9):830-9.
6. Coester LM, Saltzman CL, Leupold J et al. Long-term results following ankle arthrodesis for post-traumatic arthritis. J Bone Joint Surg Am 2001; 83-A(2):219-28.
7. Buchner M, Sabo D. Ankle fusion attributable to posttraumatic arthrosis: a long-term followup of 48 patients. Clin Orthop Relat Res 2003; (406):155-64.
8. Takakura Y, Tanaka Y, Sugimoto K et al. Long-term results of arthrodesis for osteoarthritis of the ankle. Clin Orthop Relat Res 1999; (361):178-85.
9. Gougoulias N, Khanna A, Maffulli N. How successful are current ankle replacements?: a systematic review of the literature. Clin Orthop Relat Res 2010; 468(1):199-208.
10. Spirt AA, Assal M, Hansen ST, Jr. Complications and failure after total ankle arthroplasty. J Bone Joint Surg Am 2004; 86-A(6):1172-8.
11. Pyevich MT, Saltzman CL, Callaghan JJ et al. Total ankle arthroplasty: a unique design. Two to twelve-year follow-up. J Bone Joint Surg Am 1998; 80(10):1410-20.
12. Conti SF, Bisignani G, Martin R. Update on total ankle replacement. Semin Arthroplasty 1999; 10(2):62-71.
13. Kopp FJ, Patel MM, Deland JT et al. Total ankle arthroplasty with the Agility prosthesis: clinical and radiographic evaluation. Foot Ankle Int 2006; 27(2):97-103.
14. Glazebrook MA, Arsenault K, Dunbar M. Evidence-based classification of complications in total ankle arthroplasty. Foot Ankle Int 2009; 30(10):945-9.
15. Jensen NC, Linde F. Long-term follow-up on 33 TPR ankle joint replacements in 26 patients with rheumatoid arthritis. Foot Ankle Surg 2009; 15(3):123-6.
16. Wood PL, Sutton C, Mishra V et al. A randomised, controlled trial of two mobile-bearing total ankle replacements. J Bone Joint Surg Br 2009; 91(1):69-74.
17. U.S. Food and Drug Administration. STAR Ankle Premarket Approval Panel Meeting Presentation 4-24-07. 2007. Available online at: <http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4299s1-01.pdf> . Last accessed August 2010.
18. Saltzman CL, Mann RA, Ahrens JE et al. Prospective controlled trial of STAR total ankle replacement versus ankle fusion: initial results. Foot Ankle Int 2009; 30(7):579-96.
19. Wood PL, Deakin S. Total ankle replacement. The results in 200 ankles. J Bone Joint Surg Br 2003; 85(3):334-41.
20. Wood PL, Prem H, Sutton C. Total ankle replacement: medium-term results in 200 Scandinavian total ankle replacements. J Bone Joint Surg Br 2008; 90(5):605-9.
21. Valderrabano V, Hintermann B, Dick W. Scandinavian total ankle replacement: a 3.7-year average followup of 65 patients. Clin Orthop Relat Res 2004; (424):47-56.
22. Anderson T, Montgomery F, Carlsson A. Uncemented STAR total ankle prostheses. Three to eight-year follow-up of fifty-one consecutive ankles. J Bone Joint Surg Am 2003; 85-A(7):1321-9.
23. Mann JA, Mann RA, Horton E. STAR Ankle: long-term results. Foot Ankle Int 2011; 32(5):473-84.
24. Fevang BT, Lie SA, Havelin LI et al. 257 ankle arthroplasties performed in Norway between 1994 and 2005. Acta Orthop 2007; 78(5):575-83.
25. Buechel FF, Sr., Buechel FF, Jr., Pappas MJ. Twenty-year evaluation of cementless mobile-bearing total ankle replacements. Clin Orthop Relat Res 2004; (424):19-26.
26. Buechel FF, Sr., Buechel FF, Jr., Pappas MJ. Ten-year evaluation of cementless Buechel-Pappas meniscal bearing total ankle replacement. Foot Ankle Int 2003; 24(6):462-72.
27. Doets HC, Brand R, Nelissen RG. Total ankle arthroplasty in inflammatory joint disease with use of two mobile-bearing designs. J Bone Joint Surg Am 2006; 88(6):1272-84.
28. San Giovanni TP, Keblish DJ, Thomas WH et al. Eight-year results of a minimally constrained total ankle arthroplasty. Foot Ankle Int 2006; 27(6):418-26.

29. Kofoed H, Lundberg-Jensen A. Ankle arthroplasty in patients younger and older than 50 years: a prospective series with long-term follow-up. *Foot Ankle Int* 1999; 20(8):501-6.
30. Bonnin M, Gaudot F, Laurent JR et al. The Salto Total Ankle Arthroplasty: Survivorship and Analysis of Failures at 7 to 11 years. *Clin Orthop Relat Res* 2010; 469(1):225-36.
31. Wood PL, Karski MT, Watmough P. Total ankle replacement: the results of 100 mobility total ankle replacements. *J Bone Joint Surg Br* 2010; 92(7):958-62.
32. Kokkonen A, Ikavalko M, Tiihonen R et al. High rate of osteolytic lesions in medium-term followup after the AES total ankle replacement. *Foot Ankle Int* 2011; 32(2):168-75.
33. Rodriguez D, Bevernage BD, Maldague P et al. Medium term follow-up of the AES ankle prosthesis: High rate of asymptomatic osteolysis. *Foot Ankle Surg* 2010; 16(2):54-60.
34. American Orthopaedic Foot and Ankle Society (AOFAS). Position statement: Total ankle replacement surgery. 2009. Available online at: <http://www.aofas.org/medical-community/health-policy/Pages/Total-Ankle-Replacement-Surgery.aspx> . Last accessed August 2011.
35. Brunner S, Barg A, Knupp M et al. The Scandinavian total ankle replacement: long-term, eleven to fifteen-year, survivorship analysis of the prosthesis in seventy-two consecutive patients. *J Bone Joint Surg Am* 2013; 95(8):711-8.